EGR2 gene-linked hereditary neuropathies present with a bimodal age distribution at symptoms onset.
Charcot-Marie-Tooth disease
EGR2
demyelination
Journal
Journal of the peripheral nervous system : JPNS
ISSN: 1529-8027
Titre abrégé: J Peripher Nerv Syst
Pays: United States
ID NLM: 9704532
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
07
06
2023
received:
03
05
2023
accepted:
08
06
2023
medline:
7
9
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
ppublish
Résumé
Mutations in the Early-Growth Response 2 (EGR2) gene cause various hereditary neuropathies, including demyelinating Charcot-Marie-Tooth (CMT) disease type 1D (CMT1D), congenital hypomyelinating neuropathy type 1 (CHN1), Déjerine-Sottas syndrome (DSS), and axonal CMT (CMT2). In this study, we identified 14 patients with heterozygous EGR2 mutations diagnosed between 2000 and 2022. Mean age was 44 years (15-70), 10 patients were female (71%), and mean disease duration was 28 years (1-56). Disease onset was before age 15 years in nine cases (64%), after age 35 years in four cases (28%), and one patient aged 26 years was asymptomatic (7%). All symptomatic patients had pes cavus and distal lower limbs weakness (100%). Distal lower limbs sensory symptoms were observed in 86% of cases, hand atrophy in 71%, and scoliosis in 21%. Nerve conduction studies showed a predominantly demyelinating sensorimotor neuropathy in all cases (100%), and five patients needed walking assistance after a mean disease duration of 50 years (47-56) (36%). Three patients were misdiagnosed as inflammatory neuropathy and treated with immunosuppressive drugs for years before diagnosis was corrected. Two patients presented with an additional neurologic disorder, including Steinert's myotonic dystrophy and spinocerebellar ataxia (14%). Eight EGR2 gene mutations were found, including four previously undescribed. Our findings demonstrate EGR2 gene-related hereditary neuropathies are rare and slowly progressive demyelinating neuropathies with two major clinical presentations, including a childhood-onset variant and an adult-onset variant which may mimic inflammatory neuropathy. Our study also expands the genotypic spectrum of EGR2 gene mutations.
Sections du résumé
BACKGROUND
Mutations in the Early-Growth Response 2 (EGR2) gene cause various hereditary neuropathies, including demyelinating Charcot-Marie-Tooth (CMT) disease type 1D (CMT1D), congenital hypomyelinating neuropathy type 1 (CHN1), Déjerine-Sottas syndrome (DSS), and axonal CMT (CMT2).
METHODS
In this study, we identified 14 patients with heterozygous EGR2 mutations diagnosed between 2000 and 2022.
RESULTS
Mean age was 44 years (15-70), 10 patients were female (71%), and mean disease duration was 28 years (1-56). Disease onset was before age 15 years in nine cases (64%), after age 35 years in four cases (28%), and one patient aged 26 years was asymptomatic (7%). All symptomatic patients had pes cavus and distal lower limbs weakness (100%). Distal lower limbs sensory symptoms were observed in 86% of cases, hand atrophy in 71%, and scoliosis in 21%. Nerve conduction studies showed a predominantly demyelinating sensorimotor neuropathy in all cases (100%), and five patients needed walking assistance after a mean disease duration of 50 years (47-56) (36%). Three patients were misdiagnosed as inflammatory neuropathy and treated with immunosuppressive drugs for years before diagnosis was corrected. Two patients presented with an additional neurologic disorder, including Steinert's myotonic dystrophy and spinocerebellar ataxia (14%). Eight EGR2 gene mutations were found, including four previously undescribed.
INTERPRETATION
Our findings demonstrate EGR2 gene-related hereditary neuropathies are rare and slowly progressive demyelinating neuropathies with two major clinical presentations, including a childhood-onset variant and an adult-onset variant which may mimic inflammatory neuropathy. Our study also expands the genotypic spectrum of EGR2 gene mutations.
Substances chimiques
EGR2 protein, human
0
Early Growth Response Protein 2
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-367Informations de copyright
© 2023 Peripheral Nerve Society.
Références
Bellone E, Di Maria E, Soriani S, et al. A novel mutation (D305V) in the early growth response 2 gene is associated with severe Charcot-Marie-Tooth type 1 disease. Hum Mutat. 1999;14:353-354.
Funalot B, Topilko P, Arroyo MA, et al. Homozygous deletion of an EGR2 enhancer in congenital amyelinating neuropathy. Ann Neurol. 2012;71:719-723.
Gargaun E, Seferian AM, Cardas R, et al. EGR2 mutation enhances phenotype spectrum of Dejerine-Sottas syndrome. J Neurol. 2016;263:1456-1458.
Shiga K, Noto Y, Mizuta I, Hashiguchi A, Takashima H, Nakagawa M. A novel EGR2 mutation within a family with a mild demyelinating form of Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2012;17:206-209.
Timmerman V, De Jonghe P, Ceuterick C, et al. Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology. 1999;52:1827-1832.
Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet. 1998;18:382-384.
Warner LE, Svaren J, Milbrandt J, Lupski JR. Functional consequences of mutations in the early growth response 2 gene (EGR2) correlate with severity of human myelinopathies. Hum Mol Genet. 1999;8:1245-1251.
Grosz BR, Golovchenko NB, Ellis M, et al. A de novo EGR2 variant, c.1232A > G p.Asp411Gly, causes severe early-onset Charcot-Marie-Tooth neuropathy type 3 (Dejerine-Sottas neuropathy). Sci Rep. 2019;9:19336.
Nagarajan R, Svaren J, Le N, et al. EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron. 2001;30:355-368.
Safka Brožková D, Nevšímalová S, Mazanec R, Rautenstrauss B, Seeman P. Charcot-Marie-Tooth neuropathy due to a novel EGR2 gene mutation with mild phenotype. Usefulness of human mapping chip linkage analysis in a Czech family. Neuromuscul Disord. 2012;22:742-746.
Mikesová E, Hühne K, Rautenstrauss B, et al. Novel EGR2 mutation R359Q is associated with CMT type 1 and progressive scoliosis. Neuromuscul Disord. 2005;15:764-767.
Tozza S, Magri S, Pennisi EM, et al. A novel family with axonal Charcot-Marie-Tooth disease caused by a mutation in the EGR2 gene. J Peripher Nerv Syst. 2019;24:219-223.
Sevilla T, Sivera R, Martínez-Rubio D, et al. The EGR2 gene is involved in axonal Charcot-Marie-Tooth disease. Eur J Neurol. 2015;22:1548-1555.
Lupo V, Won S, Frasquet M, et al. Bi-allelic mutations in EGR2 cause autosomal recessive demyelinating neuropathy by disrupting the EGR2-NAB complex. Eur J Neurol. 2020;27:2662-2667.
Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35:1978-1980.
Hauw F, Fargeot G, Adams D, et al. Charcot-Marie-Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: an international multicentric retrospective study. Eur J Neurol. 2021;28:2846-2854.
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. Eur J Neurol. 2021;28:3556-3583.
Fusco C, Spagnoli C, Salerno GG, et al. Charcot-Marie-Tooth disease with pyramidal features due to a new mutation of EGR2 gene. Acta Biomed. 2019;90:104-107.
Chu XJ, Du K, Meng LC, et al. EGR2-related mixed demyelinating and axonal Charcot-Marie-Tooth disease: an electrodiagnostic, nerve imaging, and histological study. Clin Neuropathol. 2022;41:245-252.
Moss KR, Bopp TS, Johnson AE, Höke A. New evidence for secondary axonal degeneration in demyelinating neuropathies. Neurosci Lett. 2021;744:135595.
Wang J, Wang J, Yang L, et al. CTCF-mediated chromatin looping in EGR2 regulation and SUZ12 recruitment critical for peripheral myelination and repair. Nat Commun. 2020;11:4133.
Wüst HM, Wegener A, Fröb F, et al. Egr2-guided histone H2B monoubiquitination is required for peripheral nervous system myelination. Nucleic Acids Res. 2020;48:8959-8976.